PYC Therapeutics Ltd PYC
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- A$2.68
- Day Range
- A$2.46–2.73
- 52-Week Range
- A$1.05–2.93
- Bid/Ask
- A$2.46 / A$2.47
- Shares Outstanding
- 983.51M
- Market Cap
- A$2.42B
- Volume/Avg
- 6M / 3M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
PYC Therapeutics Ltd is a clinical-stage biotechnology company creating a new generation of RNA therapies for patients with genetic diseases. The Group is engaged in drug development and progressing the Company's drug pipeline through preclinical and clinical development. The Company operates in a single business segment comprising the discovery and development of novel RNA therapeutics, with a single geographical location in Australia.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Mid Growth
- Total Number of Employees
- 5
- Website
- https://www.pyctx.com
Valuation
|
Metric
|
PYC
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 3.80 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
PYC
|
|---|---|
Quick Ratio | 33.44 |
Current Ratio | 33.48 |
Interest Coverage | −1,418.94 |
Quick Ratio
PYC
Profitability
|
Metric
|
PYC
|
|---|---|
Return on Assets (Normalized) | −11.58% |
Return on Equity (Normalized) | −12.05% |
Return on Invested Capital (Normalized) | −16.05% |
Return on Assets
PYC
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|JT<<wT | LOCK|Qpyz | $127B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|?P@r??Q | LOCK|!!#R | $76B | |||
| Moderna Inc
MRNA
| LOCK|GRHMSL | LOCK|gDG | $75B | |||
| argenx SE ADR
ARGX
| LOCK|PG>n<f | LOCK|^T? | $59B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|?>N#Y$ | LOCK|C> | $43B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|wL!R%> | LOCK|rH#Yy | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|z&#@k^pr | LOCK|T@cP | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|B#HkHCw | LOCK|^$ | $24B | |||
| Incyte Corp
INCY
| LOCK|>C#dmBM | LOCK|vM | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|<!N>>& | LOCK|MY | $15B |
United States